Hikal Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/t58jyq70mc1808e9t8pvc729.pdf

Key Takeaways


Pharma: Recovery Taking Shape

Sameer Hiremath: "First, I think operating leverage itself will improve our margins from where we are today. Currently, the plants are not fully utilized because of the global macro crisis taking place. Once we get that back into steady state, then already operating leverage will improve our margins and the new products that come in to fold in the next 3 to 4 years, we'll have a better margin profile. The blended margin will be higher than historical margins on a stepwise basis, they're moving towards that, yes."

Crop Protection: Waiting for the Cycle

Sameer Hiremath: "Crop is undergoing massive stress as we know. It is going to be Q3 or Q4 of the year that anyone's guess."

Animal Health: The Long-Gestation Growth Engine

Anish Swadi: "So in the initial stages, the margin will creep up to where the company margin is once it stabilizes, right?"

CDMO: The Margin Story Beneath the Surface

Sameer Hiremath: "It's a fixed margin and RM is just passthrough, but the margins are significantly higher than the current company margins here on the CDMO. Because these are... Sorry, it is percentage, but the RM is passthrough. But RM is a small part of the total cost because it's on patent. So margins are pretty high."

Capex & Capacity: Front-Loaded for Growth


Guidance & Commitments

CommitmentSpecificsTimeline
Demand normalizationRecovery expected toward end of H1 FY25End of H1 FY25
Pharma margin recoveryAPI and CDMO margins back to historical levelsH2 FY25
Crop Protection recoveryImprovement from Q3 FY25 onward, per current estimateQ3 FY25 onward
CDMO product ramp-up3–4 products under development to begin contributingH2 FY25
CWIP operationalINR 500 crores CWIP to become operationalBy Q2 FY25
Animal Health revenueINR 200–300 crores potential from new plant3–4 years out
Long-term revenueINR 3,000–3,200 crores targetFY27–28
Capex spend (FY24)INR 200 crores target, INR 170 crores doneBalance in Q4 FY24
API product launches3–4 products per year from 8–10 product pipelineAnnual cadence

Key Metrics

MetricQ3 FY24
Revenue₹448 cr
EBITDA₹65 cr
EBITDA margin14.5%, up 70 bps YoY
9M FY24 revenue₹1,271 cr
9M FY24 EBITDA₹173 cr
9M FY24 EBITDA margin13.6%, up 230 bps YoY
Interim dividend30% for FY24
Pharma segment revenue₹267 cr
Pharma segment EBIT margin6.9%
Pharma segment 9M FY24 revenue₹763 cr
Pharma segment 9M FY24 EBIT margin5.2%
Pharma operating profit sequential growth56% QoQ
Crop Protection segment revenue₹180 cr
Crop Protection segment EBIT margin12.1%
Crop Protection segment 9M FY24 revenue₹508 cr
Crop Protection segment 9M FY24 EBIT margin11.9%
CDMO share of total revenueOver 50%
Company volume changeDown 9% YoY, down 6% QoQ
Crop Protection volume changeDown 10% QoQ
Pharma volume changeDown 2% QoQ
Pharma plant utilization75% to 80%
Capex incurred in 9M FY24~₹170 cr of the ₹200 cr annual target
Typical annual capex₹150 cr to ₹200 cr
CWIP~₹500 cr
Animal Health potential revenue in 3–4 years₹200 cr to ₹300-odd cr
FY23 revenueCrossed ₹2,000 cr (per an analyst's math)